乳腺癌的分子核医学研究进展  

Research progress of molecular nuclear medicine imaging in breast cancer

作　　者：李翠翠 杨琦 王荣福[1] 康磊[1] Cuicui Li;Qi Yang;Rongfu Wang;Lei Kang(Department of Nuclear Medicine,Peking University First Hospital,Beijing 100034,China;Department of Nuclear Medicine,Beijing Friendship Hospital of Capital Medical University,Beijing 100050,China)

机构地区：[1]北京大学第一医院核医学科,北京市100034 [2]首都医科大学附属北京友谊医院核医学科

出　　处：《中国肿瘤临床》2022年第4期193-196,共4页Chinese Journal of Clinical Oncology

基　　金：国家自然科学基金面上项目(编号:81871385)资助。

摘　　要：乳腺癌是一种具有高度异质性、高发病率、高死亡率的癌症。个体化的早期准确诊断和治疗是提高患者生存率的有效手段。分子核医学将分子生物学技术与核医学相结合,在分子、细胞、活体水平对机体生物学行为进行定性和定量研究,是一种高度可重复、安全且无创的影像技术,广泛应用于各种恶性肿瘤的诊断、分期、预后预测和疗效评估。本文主要对分子核医学代谢显像、受体显像、基因显像和免疫PET显像在乳腺癌中的应用进行综述。Breast cancer is a high incidence and mortality cancer with high heterogeneity.Early accurate diagnosis and individualized treatment are effective means to improve the survival rate of patients.Molecular nuclear medicine imaging combines molecular biology technology with nuclear medicine,qualitative and quantitative studying the biological behavior of cancer in molecules,cells and living levels.It is a highly repeatable,safe and non-invasive imaging,which is widely used in the diagnosis,staging,prognosis prediction and efficacy evaluation of various malignant tumors.This article reviewed the molecular nuclear medicine of breast cancer,including metabolic,receptor,gene and immunoPET imaging.

关 键 词：乳腺癌 分子核医学 代谢显像 受体显像 免疫PET显像 

分 类 号：R737.9[医药卫生—肿瘤]